Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
30.46
+0.84 (2.84%)
Sep 30, 2025, 4:08 PM HKT
HKG:1877 Revenue
Shanghai Junshi Biosciences had revenue of 667.79M CNY in the quarter ending June 30, 2025, with 64.78% growth. This brings the company's revenue in the last twelve months to 2.33B, up 43.96% year-over-year. In the year 2024, Shanghai Junshi Biosciences had annual revenue of 1.95B with 29.67% growth.
Revenue (ttm)
2.33B CNY
Revenue Growth
+43.96%
P/S Ratio
16.69
Revenue / Employee
904.05K CNY
Employees
2,578
Market Cap
42.62B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.95B | 445.77M | 29.67% |
Dec 31, 2023 | 1.50B | 49.06M | 3.38% |
Dec 31, 2022 | 1.45B | -2.57B | -63.89% |
Dec 31, 2021 | 4.02B | 2.43B | 152.36% |
Dec 31, 2020 | 1.59B | 819.81M | 105.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
WuXi Biologics | 21.98B |
Innovent Biologics | 12.52B |
Sino Biopharmaceutical | 33.49B |
Akeso | 2.75B |
Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |